公开(公告)号：US11304944B2

公开(公告)日：2022-04-19

申请号：US16752908

申请日：2020-01-27

申请人： SynDevRx, Inc.

发明人： John S. Petersen ,  James Shanahan

IPC分类号： A61K31/77 ,  A61K31/485 ,  A61K47/65 ,  A61K47/54 ,  A61K47/58 ,  A61P3/10 ,  A61P3/04 ,  A61P3/08 ,  A61P5/50 ,  A61K31/336

摘要： The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.

公开(公告)号：US11279915B2

公开(公告)日：2022-03-22

申请号：US16245298

申请日：2019-01-11

申请人： Maine Medical Center Research Institute

发明人： Aaron C. Brown

IPC分类号： C12N5/077 ,  A61K35/35 ,  A61K38/20 ,  A61K45/06 ,  A61P3/10 ,  A61P3/04 ,  A61P3/06

摘要： Provided herein are, inter alia, methods, compositions, and kits for producing adipocyte populations such as beige adipocyte populations. Also included are methods and compositions for increasing the level of adipocyte populations (e.g., beige adipocyte populations) in a subject, as well as methods and compositions for treating subjects who are overweight, obese, or who have diabetes.

公开(公告)号：US11278525B1

公开(公告)日：2022-03-22

申请号：US16161024

申请日：2018-10-15

申请人： SirTLab Corporation

发明人： Haim Yosef Cohen ,  Yariv Kanfi

IPC分类号： A61K31/423 ,  A61P3/00 ,  A61P3/04 ,  A61P3/06 ,  A61K31/433

摘要： A SIRT6 activating molecule as shown in Tables 1-3 and 9, or a compound according to a pharmacophore as described herein.

公开(公告)号：US11273166B2

公开(公告)日：2022-03-15

申请号：US16622348

申请日：2018-06-13

申请人： Monash University

发明人： Garron Dodd ,  Tony Tiganis

IPC分类号： A61K31/575 ,  A61P3/04 ,  A61K9/00 ,  A61K31/15 ,  A61K31/662 ,  C12N15/113 ,  A61P5/04

摘要： The present invention generally relates to methods and compositions for the treatment of overweight or obese individuals. In particular, the invention relates to reducing adiposity of an overweight or obese individual. The present invention provides a method for reducing adiposity or treating obesity in an individual, the method comprising inhibiting TCPTP and/or PTP1B in the hypothalamus of the individual, thereby reducing adiposity or treating obesity in the individual.

公开(公告)号：US11266706B2

公开(公告)日：2022-03-08

申请号：US16760787

申请日：2018-08-09

申请人： AMOREPACIFIC CORPORATION

发明人： Ayoung Kim ,  Hyun Woo Jeong ,  Yong-Deog Hong ,  Jeong-Kee Kim

IPC分类号： A61K36/82 ,  A61P1/16 ,  A61P3/04 ,  A61P3/06 ,  A61K9/00

摘要： The present specification relates to a composition containing a tea extract with an increased specific ingredient content for prevention or alleviation of lipid metabolism disorders. The use of a preparation method and a composition according to the present specification can effectively prevent and treat lipid metabolism disorders including obesity without side effects, thereby meeting related demands and promoting the development of corresponding industries.

公开(公告)号：US20220062215A1

公开(公告)日：2022-03-03

申请号：US17413406

申请日：2019-09-27

申请人： KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION ,  KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

发明人： Gi Hoon SON ,  Jong Hwa JUNG

IPC分类号： A61K31/216 ,  A61P25/30 ,  A61P3/04

摘要： The present disclosure relates to a pharmaceutical composition for prevention or treatment of circadian rhythm-related disorders, including an oxyiminomethylbenzene derivative or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11261227B2

公开(公告)日：2022-03-01

申请号：US16812011

申请日：2020-03-06

申请人： HANMI PHARM. CO., LTD.

发明人： Jung Kuk Kim ,  Young Jin Park ,  In Young Choi ,  Sung Youb Jung

IPC分类号： A61K38/26 ,  A61K38/28 ,  C07K14/605 ,  A61K38/22 ,  A61K47/60 ,  A61K47/68 ,  A61P3/08 ,  A61P3/00 ,  A61P3/04

摘要： A glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof are disclosed.

公开(公告)号：US11236142B2

公开(公告)日：2022-02-01

申请号：US16638970

申请日：2018-08-16

申请人： DONG-A ST CO., LTD.

发明人： Jae-Sung Yang ,  Kyung-Seok Lee ,  Yu-Na Chae ,  Gye-Rim Baek ,  Tae-Hyoung Kim ,  Ill-Hun Jung ,  Chae-Lim Ryu ,  Weon-Bin Im

IPC分类号： A61K38/00 ,  C07K14/575 ,  A61P3/04 ,  A61P3/10

摘要： The present invention relates to a novel peptide analog of acylated oxyntomodulin and a pharmaceutical composition comprising the same for preventing and treating obesity or overweightness, or diabetes accompanied by obesity and overweightness. The peptides are superior to those of natural oxyntomodulin in dual agonism on GLP-1 and glucagon receptors and longer in vivo half-life. A pharmaceutical composition comprising said peptides is effective in the treatment of metabolic diseases such as obesity and diabetes mellitus.

公开(公告)号：US11224581B2

公开(公告)日：2022-01-18

申请号：US16326260

申请日：2017-08-18

申请人： Meiji Co., Ltd.

发明人： Kentaro Nakamura ,  Kinya Ashida ,  Akina Sasayama ,  Yuri Saito

IPC分类号： A61K31/195 ,  A61K31/16 ,  A61K31/198 ,  A61K31/185 ,  A23L33/175 ,  A61P25/08 ,  A61K31/23 ,  A61P35/00 ,  A61P25/16 ,  A61P25/06 ,  A61P43/00 ,  A61K31/20 ,  A61P3/04 ,  A61P9/10 ,  A61P25/00 ,  A61P25/28 ,  A61P9/04 ,  A61P3/10 ,  A61P25/24 ,  A23L33/12 ,  A61P3/02 ,  A61K31/225

摘要： An object of the present invention is to provide a novel composition for promoting ketone body production. The present invention provides a composition for use in promoting ketone body production, comprising one or more amino acid(s) selected from the group consisting of citrulline, leucine, cysteine, taurine, glutamine and aspartic acid. The composition according to the present invention may further comprise either or both of a medium-chain fatty acid and a medium-chain fatty acid ester.

公开(公告)号：US11220526B2

公开(公告)日：2022-01-11

申请号：US16090728

申请日：2017-03-23

申请人： Research Triangle Institute ,  The Regents of the University of California

发明人： Scott Runyon ,  Danni Harris ,  Rainer Reinscheid ,  Yanyan Zhang ,  Carla Hassler

IPC分类号： C07K5/068 ,  A61K38/00 ,  C07K5/083 ,  C07K5/087 ,  C07K5/097 ,  C07K5/08 ,  C07K5/103 ,  C07K7/06 ,  C07K5/107 ,  A61P25/28 ,  A61P25/30 ,  A61P3/04 ,  A61P25/18

摘要： Neuropeptide S receptor agonists are provided. The NPS agonists include trimeric, tetrameric, pentameric or hexameric peptidomimetic analogs exhibiting affinity for and activity at the neuropeptide S receptor. The peptidomimetic molecules may be useful in the treatment of disorders, syndromes and conditions mediated by modulation of the neuropeptide S receptor such as substance abuse, narcolepsy, insomnia, obesity, cognitive decline, dementia, Alzheimer's disease, panic disorder, generalized anxiety, PTSD, phobias, schizophrenia and as supportive medication during any kind of cessation program in cognitive behavioral therapy, such as drug addiction, eating disorders and gambling.